Does subcutaneous self-administration with Vivaglobin® work as well as intravenous immunoglobulin?
In a multicenter clinical trial conducted in the United States and Canada, Vivaglobin® has been proven to be similarly effective to IVIg. In the trial, 65 patients with primary immunodeficiency who had previously been treated with monthly intravenous immunoglobulin were switched for a year to weekly subcutaneous administration with Vivaglobin®. The trial showed that • A low annual rate of serious infections: 0.04 per subject per year • A low annual rate of infections overall: 4.4 per subject per year • A low annual rate of missed school and work days: 3.7 per subject per year • A low annual rate of days hospitalized due to infection, 0.23 per subject per year The trial also showed that with weekly administration, serum levels of immunoglobulin or IgG in the bloodstream were steady unlike with monthly intravenous administration. Because Vivaglobin® delivers steady serum Ig levels, people may not experience the “wear-off” effect that can occur for monthly intravenous therapy patients jus
